Physician–researcher's work yields landmark five-year data for Crohn's disease drug

A physician–scientist and national leader in inflammatory bowel disease at the University of Cincinnati has led the publication of landmark five-year efficacy and safety data for guselkumab, a biologic therapy for moderately to severely active Crohn's disease.